Aligning Expectations: Can the US FDA and Industry Meet in the Middle?
This article was originally published in SRA
The life sciences industry is poised to revolutionise healthcare over the next decade through the development of more targeted and effective treatments. To realise the potential of this healthcare revolution, pharmaceutical and medical device companies and regulators should make a greater effort to collaborate toward the goal of bringing high-demand, innovative and safe products to market, writes Michael Mentesana.
You may also be interested in...
The shifts roiling the health care industry are creating an entirely new commercial landscape. PwC says that the way pharma companies opt to address three pivotal challenges – patient engagement, analytics and value – will affect not only their future, but the future direction of patient care, provider decisions and payment mechanisms.